IWM
SNOA icon

IHT Wealth Management’s Sonoma Pharmaceuticals SNOA Stock Holding History

IHT Wealth Management’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1
Closed -$1K – 1316
2016
Q4 		$1K Buy
+1
New +$829 ﹤0.01% 1156

Other funds holding SNOA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

IHT Wealth Management's SNOA Position: Q1 2017 in Review

IHT Wealth Management sold out of Sonoma Pharmaceuticals (SNOA) in Q1 2017, closing a stake of 1 share — an estimated $1K sold.

IHT Wealth Management first reported a position in SNOA in Q4 2016 and held it in 1 quarter. The position peaked at $1K in Q4 2016. 19 funds tracked by Wall St. Rank hold SNOA as of Q1 2017.

  • IHT Wealth Management reported no remaining Sonoma Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • IHT Wealth Management sold 1 Sonoma Pharmaceuticals share in Q1 2017, an estimated $1K.
  • IHT Wealth Management first reported a position in Sonoma Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • IHT Wealth Management's Sonoma Pharmaceuticals position peaked at $1K in Q4 2016.
  • 19 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q1 2017.

Based on IHT Wealth Management's 13F filing for Q1 2017, filed 16 May 2017.